Press Releases

2025.01.08

I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member

Chairman of the Board, Wei Fu, informed the Company of his intent to purchase up to $2,000,000 of the Company’s American Depository Shares (ADSs) ROCKVILLE, MD, January 8, 2024 – I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced […]

2025.01.06

I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program

Givastomig: a Claudin 18.2 (“CLDN18.2”) x 4-1BB bispecific antibody, will be the lead clinical program following the Company’s portfolio prioritization The Company has completed enrollment of a dose escalation study of givastomig in combination with nivolumab plus chemotherapy, and data is expected in the early second half of 2025; a 40-patient dose expansion study is […]

2024.11.21

I-Mab to Participate at the Piper Sandler Healthcare Conference

The 36th Annual Healthcare Conference will be held in New York, December 3-5, 2024 ROCKVILLE, MD, November 21, 2024 – I-Mab (NASDAQ: IMAB, the “Company”), a U.S.-based global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the Piper Sandler 36th […]

Partner News

Media Reports